Aerie Pharmaceuticals With Two ROCK Inhibitors In Development
Publicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase III studies, and Roclatan, a Rhopressa-latanoprost combination that is entering a Phase III trail. ROCK inhibitors have been known to improve aqueous outflow through the trabecular meshwork and, possibly, improve blood flow to the optic nerve and delay ocular cell death in glaucoma.
Presenter:
Vicente Anido, Jr., PhD
Vicente Anido, Jr., PhD currently serves as CEO and Chairman of the Board of Aerie Pharmaceuticals, Inc., a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.